Page last updated: 2024-12-04

chlorphenesin carbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2724
CHEMBL ID607710
CHEBI ID3643
SCHEMBL ID34492
MeSH IDM0064078

Synonyms (100)

Synonym
57u5yi11wp ,
unii-57u5yi11wp
MLS002154243
smr001233511
BRD-A39230911-001-03-7
3-[(4-chlorophenyl)oxy]-2-hydroxypropyl carbamate
hsdb 3031
brn 1978575
kolpicortin-sine
3-(4-chlorophenoxy)-1,2-propanediol-1-carbamate
chlorphenesin carbamate [usan:jan]
nsc 82943
einecs 212-954-7
chlorphensin carbamate
PRESTWICK_882
NCGC00016548-01
cas-886-74-8
PRESTWICK3_000234
NCGC00179607-01
3-(p-chlorophenoxy)-2-hydroxypropyl carbamate
3-(4-chlorophenoxy)-2-hydroxypropyl carbamate
wln: zvo1yq1or dg
1, 3-(p-chlorophenoxy)-, 1-carbamate
u-19,646
3-(p-chlorophenoxy)-1,2-propanediol-1-carbamate
1, 3-(4-chlorophenoxy)-, 1-carbamate
nsc82943
u 19646
carbamic acid, 3-(p-chlorophenoxy)-2-hydroxypropyl ester
rinlaxer
(3-p-chlorophenoxy)-2-hydroxypropylcarbamate
nsc-82943
3-(p-chlorophenoxy)-1,2-propanediol 1-carbamate
maolate
[3-(4-chlorophenoxy)-2-hydroxy-propyl] carbamate
1,2-propanediol, 3-(p-chlorophenoxy)-, 1-carbamate
1,2-propanediol, 3-(4-chlorophenoxy)-, 1-carbamate
PRESTWICK2_000234
BPBIO1_000339
BSPBIO_000307
C07930
chlorphenesin carbamate ,
886-74-8
D00770
maolate (tn)
chlorphenesin carbamate (jp17/usan)
PRESTWICK1_000234
PRESTWICK0_000234
SPBIO_002228
CHEBI:3643 ,
carbamic acid 3-(p-chlorophenoxy)-2-hydroxypropyl ester
1,2-propanediol-3-(p-chlorophenoxy)-1-carbamate
HMS1568P09
CHEMBL607710
u-19646
[3-(4-chlorophenoxy)-2-hydroxypropyl] carbamate
HMS2095P09
tox21_110487
dtxcid002803
dtxsid5022803 ,
HMS2232O23
FT-0602972
1,2-propanediol,3-(4-chlorophenoxy)-, 1-carbamate
HMS3371A08
chlorphenesin carbamate [hsdb]
chlorphenesin carbamate [jan]
chlorphenesin carbamate [who-dd]
chlorphenesin carbamate [green book]
chlorphenesin carbamate [mi]
chlorphenesin carbamate [vandf]
chlorphenesin carbamate [orange book]
chlorphenesin carbamate [mart.]
chlorphenesin carbamate [usan]
CCG-220234
SCHEMBL34492
NCGC00179607-03
W-100393
chlorphenesincarbamate
sr-01000841824
SR-01000841824-2
HMS3712P09
DB14656
126632-50-6
chlorphenesin carbamate, (-)-
hqc4wi89yg ,
unii-hqc4wi89yg
1,2-propanediol, 3-(4-chlorophenoxy)-, 1-carbamate, (-)-
Q27106156
maolate; nsc 82943; rhnesicn; rinlaxer; u 19646; u-19,646
chlorphenesin carbamate, (+)-
1,2-propanediol, 3-(4-chlorophenoxy)-, 1-carbamate, (+)-
G014XC07GH
HY-107944
EN300-23982086
CS-0030953
GLXC-26272
(2rs)-3-(4-chlorophenoxy)-2-hydroxypropyl carbamate
chlorphenesin carbamate (mart.)
maolate tablets, maolate veterinary
AKOS040744828

Research Excerpts

Overview

Chlorphenesin carbamate is a skeletal muscle relaxant approved in Korea for use in the treatment of pain and discomfort related to skeletal muscle trauma.

ExcerptReferenceRelevance
"Chlorphenesin carbamate is a skeletal muscle relaxant approved in Korea for use in the treatment of pain and discomfort related to skeletal muscle trauma and inflammation."( Relative bioavailability of generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in healthy Korean volunteers: a single-dose, randomized-sequence, open-label, two-period crossover trial.
Choi, KS; Kim, BG; Kwon, YE; Park, HJ; Song, HH; Yu, JY, 2009
)
2.03

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency12.52730.004110.890331.5287AID504466; AID504467
AR proteinHomo sapiens (human)Potency7.16690.000221.22318,912.5098AID743042
Smad3Homo sapiens (human)Potency0.10000.00527.809829.0929AID588855
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.16690.000229.305416,493.5996AID743080
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID287367Distribution coefficient, log D at pH 7.42007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID287368Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
The synthesis of amphipathic prodrugs of 1,2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (48.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.00)29.6817
2010's8 (32.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.22 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.45%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.45%)4.05%
Observational0 (0.00%)0.25%
Other27 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]